Synergistic interplay and dual-target therapeutics: unraveling the coordinated network of SIK2 and PARP-1 in cancer development
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.109244 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Long-Tian Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang 110004, PR China. Hauptthemen laut MEDLINE: Poly (ADP-Ribose) Polymerase-1, Neoplasms, Protein Serine-Threonine Kinases, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 88 Literaturangaben. Gefördert von: China International Medical Foundation, China Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Salt-inducible kinase 2 (SIK2) and poly (ADP-ribose) polymerase 1 (PARP-1) form an unexpected, intricate synergistic network driving tumorigenesis, therapy resistance, and immune evasion, positioning their co-inhibition as a transformative strategy to overcome fundamental limitations in current cancer therapy. Mounting mechanistic evidence underscores their synergistic interplay in perpetuating genomic instability, enhancing tumor cell survival under replicative stress, and evading immune surveillance. Critically, emerging data suggest that SIK2 and PARP-1 engage in a functionally integrated regulatory network extending beyond their roles, collectively driving tumor progression and resistance. Simultaneous targeting of these nodes may thus yield unique therapeutic advantages by overcoming the intrinsic limitations of conventional therapies. This review integrates mechanistic insights, structural biology, and drug design perspectives to establish a novel framework for developing dual SIK2/PARP-1 inhibitors, offering a promising path to redefine treatment paradigms for recalcitrant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang 110004, PR China.
- School of Pharmacy, China Medical University, Shenyang 110122, PR China. Electronic address: fhmeng@cmu.edu.cn.
- Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang 110004, PR China. Electronic address: 20202420@cmu.edu.cn.
Förderung
- China International Medical Foundation
- China Medical University
- National Natural Science Foundation of China
Zitieren
APA
Li, L. T., Zhang, S. C., Yang, Y. Y., Zhang, J. F., Meng, F. H., & Li, X. Y. (2025). Synergistic interplay and dual-target therapeutics: unraveling the coordinated network of SIK2 and PARP-1 in cancer development. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.109244
Vancouver
Li LT, Zhang SC, Yang YY, Zhang JF, Meng FH, Li XY. Synergistic interplay and dual-target therapeutics: unraveling the coordinated network of SIK2 and PARP-1 in cancer development. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.109244
BibTeX
@article{Li2025,
author = {Li, Long-Tian and Zhang, Shi-Chen and Yang, Yue-Ying and Zhang, Ji-Fang and Meng, Fan-Hao and Li, Xin-Yang},
title = {Synergistic interplay and dual-target therapeutics: unraveling the coordinated network of SIK2 and PARP-1 in cancer development},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.109244}
}
EUVIMED